Glasdegib

Glasdegib
Clinical data
Other names	PF-04449913
Legal status
Legal status	US: WARNING;
Identifiers
	IUPAC name 1-[(2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methyl-4-piperidinyl]-3-(4-cyanophenyl)urea;
CAS Number	1095173-27-5;
ChemSpider	28518072;
KEGG	D10636 ;
CompTox Dashboard (EPA)	DTXSID201025881 ;
ECHA InfoCard	100.244.738
Chemical and physical data
Formula	C21H22N6O
Molar mass	374.448 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CC[C@H](C[C@@H]1c2[nH]c3ccccc3n2)NC(=O)Nc4ccc(cc4)C#N;
	InChI InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1; Key:SFNSLLSYNZWZQG-VQIMIIECSA-N;

Glasdegib (PF-04449913) is an experimental cancer drug developed by Pfizer. It is a small molecule inhibitor of the Sonic hedgehog pathway, which is overexpressed in many types of cancer. It inhibits smoothened receptor, as do most drug in its class.^[2]

Four phase II clinical trials are in progress. One is evaluating the efficacy of glasdegib in treating myelofibrosis in patients who were unable to control the disease with ruxolitinib.^[3] Another is a combination trial of glasdenib with ARA-C, decitabine, daunorubicin, or cytarabine for the treatment of acute myeloid leukemia.^[4] The third is for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.^[5] The fourth administers glasdegib to patients at high risk for relapse after stem cell transplants in acute lymphoblastic or myelogenous leukemia.^[6]

References

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Glasdegib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
^ "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
^ "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
^ "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
^ "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

This oncology article is a stub. You can help Wikipedia by expanding it.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[2] "Glasdegib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.

[3] "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

[4] "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

[5] "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

[6] "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.

[1]

[2]

[3]

[4]

[5]

[6]